Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -744.2%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $58M | $167M | $90M | — | — | — | — | — |
| Enterprise Value | $38M | $147M | $85M | — | — | — | — | — |
| P/E Ratio → | -0.43 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 964.47 | — | — | — | — | — |
| P/B Ratio | 6.46 | 17.64 | 3.16 | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 911.09 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 46.2% | 35.8% | — | — | — | — |
| Operating Margin | — | — | -100571.0% | -42363.3% | — | — | — | — |
| Net Profit Margin | — | — | -73864.5% | -64242.5% | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -744.2% | -744.2% | -241.7% | — | — | — | -203.9% | — |
| ROA | -122.8% | -122.8% | -74.6% | -112.4% | -56.8% | -56.4% | -139.5% | -342.4% |
| ROIC | -1115.0% | -1115.0% | -363.5% | -374.7% | -1557.2% | -8182.0% | — | — |
| ROCE | -101.2% | -101.2% | -122.0% | -85.7% | -74.5% | -71.9% | -197.2% | -541.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 6.52 | 6.52 | 2.20 | — | — | — | 1.02 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -2.10 | -0.17 | — | — | — | -0.92 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -25.61 | -19.27 | -47.12 |
Net cash position: cash ($82M) exceeds total debt ($62M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.78 | 4.78 | 3.63 | 3.19 | 7.06 | 4.07 | 2.83 | 1.99 |
| Quick Ratio | 4.78 | 4.78 | 3.63 | 3.18 | 7.06 | 4.07 | 2.83 | 1.99 |
| Cash Ratio | 4.45 | 4.45 | 3.41 | 3.00 | 6.74 | 4.04 | 2.67 | 1.70 |
| Asset Turnover | — | — | 0.00 | 0.00 | — | — | — | — |
| Inventory Turnover | — | — | 0.68 | 1.05 | — | — | — | — |
| Days Sales Outstanding | — | — | — | 66.92 | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — | — | — |
| Shares Outstanding | — | $76M | $44M | $48M | $48M | $48M | $48M | $48M |
Clinical trial funding dependency
According to recent financial data, GUTS trades at a price-to-book ratio of 6.14, reflecting a market valuation that appears to be a speculative call option on future clinical success rather than a reflection of current fundamental earnings power or tangible asset value in the biotechnology sector.
The absence of meaningful P/E or P/S multiples underscores the firm's pre-commercial status, where valuation is driven entirely by the perceived probability of regulatory approval for the Revita system. Investors should monitor whether this premium holds as the company approaches critical clinical milestones, as any delay could lead to significant multiple compression.
Based on reported figures, the company's ROIC has remained deeply negative, fluctuating between -61.4% and -98.4% over the last several quarters, which indicates that the firm is currently destroying capital as it funds extensive R&D and clinical trial activities without any offsetting operational returns.
The inability to generate positive returns on invested capital is a structural reality for a pre-revenue biotech, but the magnitude of these losses warrants caution. Until the Revita system achieves commercial viability, these metrics will likely remain a reflection of cash burn rather than true capital efficiency.
As reported in financial statements, the current ratio has compressed from a peak of 9.38 in 2024Q1 to 4.28 by 2026Q1, suggesting that while the firm maintains a short-term liquidity cushion, the rapid depletion of cash reserves is narrowing the window for successful commercialization.
The decline in the current ratio reflects the ongoing consumption of cash to fund the REVITALIZE-1 trial. Investors should monitor the cash runway closely, as the current liquidity position may necessitate further dilutive financing before the company can reach a self-sustaining revenue inflection point.
According to quarterly data, the debt-to-equity ratio has risen to 2.84 as of 2026Q1, indicating that the company is increasingly relying on debt financing to bridge the gap between its current developmental stage and potential future commercialization in a highly competitive metabolic treatment market.
This leverage profile is particularly concerning given the lack of operating cash flow to service debt obligations. The reliance on external capital suggests that the firm's financial flexibility is constrained, leaving it vulnerable to shifts in credit market conditions or delays in clinical trial progress.
As indicated by financial disclosures, the use of P/E ratios to evaluate GUTS is fundamentally flawed, as the company's negative earnings are a byproduct of necessary R&D investment rather than operational failure, obscuring the true value of the underlying intellectual property and clinical pipeline.
Analysts should instead focus on cash burn rates and clinical trial milestones, as these metrics provide a more accurate assessment of the company's survival and potential for future value creation. Relying on traditional profitability ratios in this context risks misinterpreting a developmental-stage investment as a failing business.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying GUTS stock.
Fractyl Health, Inc. Common Stock's current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Fractyl Health, Inc. Common Stock's return on equity (ROE) is -744.2%. The historical average is -222.8%.
Based on historical data, Fractyl Health, Inc. Common Stock is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.